We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

75 hedge funds and large institutions have $585M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

307% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $258K

138% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 13

74% more capital invested

Capital invested by funds: $335M → $585M (+$250M)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

46% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 13

9% more funds holding

Funds holding: 69 → 75 (+6)

Holders
75
Holders Change
+6
Holders Change %
+8.7%
% of All Funds
1.87%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.15%
New
19
Increased
31
Reduced
13
Closed
13
Calls
$1.05M
Puts
$258K
Net Calls
+$792K
Net Calls Change
+$792K

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$60M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$14.2M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$13M
4
Citadel Advisors
Citadel Advisors
Florida
+$6.18M
5
PA
Perceptive Advisors
New York
+$5.65M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$13.7M
2
EA
Emerald Advisers
Pennsylvania
-$7.72M
3
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$4.62M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.74M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
26
Nicholas Investment Partners
California
$3.6M +$4.52K +149 +0.2%
GGHC
27
Gilder Gagnon Howe & Co
New York
$2.79M -$76.8K -2,532 -3%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.35M +$315K +10,398 +20%
EU
29
Emory University
Georgia
$2.17M +$1.76M +57,938 New
EAM
30
Eventide Asset Management
Massachusetts
$1.99M – – –
Norges Bank
31
Norges Bank
Norway
$1.87M – – –
AG
32
Artal Group
Luxembourg
$1.87M +$1.52M +50,000 New
Charles Schwab
33
Charles Schwab
California
$1.43M +$58.6K +1,933 +5%
American Century Companies
34
American Century Companies
Missouri
$1.38M -$595K -19,618 -35%
Wells Fargo
35
Wells Fargo
California
$1.34M +$291K +9,594 +37%
AA
36
ALPS Advisors
Colorado
$1.32M +$131K +4,309 +14%
TA
37
Teachers Advisors
New York
$1.2M +$434K +14,308 +80%
CIP
38
Chartwell Investment Partners
Pennsylvania
$1.01M +$824K +27,164 New
Morgan Stanley
39
Morgan Stanley
New York
$1.01M +$467K +15,382 +133%
PAM
40
Panagora Asset Management
Massachusetts
$918K +$250K +8,248 +51%
MIM
41
Monashee Investment Management
Massachusetts
$748K -$1.5M -49,390 Closed
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$710K – – –
Deutsche Bank
43
Deutsche Bank
Germany
$683K +$158K +5,201 +40%
SO
44
STRS Ohio
Ohio
$680K +$464K +15,300 +528%
PPA
45
Parametric Portfolio Associates
Washington
$666K +$540K +17,817 New
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$635K -$21.2K -700 -4%
RJA
47
Raymond James & Associates
Florida
$589K +$1.24K +41 +0.3%
SPC
48
Sigma Planning Corp
Michigan
$561K +$455K +15,003 New
EMG
49
Ellington Management Group
Connecticut
$538K +$437K +14,400 New
Renaissance Technologies
50
Renaissance Technologies
New York
$531K +$431K +14,200 New
1
2
3 4

BHVN Hedge Fund Activity: Q3 2017 in Review

75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2017, worth a combined $585M — up 74% from $335M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new BHVN positions and 13 closed out — a net gain of 6 holders — while 31 added to existing stakes and 13 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $60M. The largest seller was RA Capital Management, cutting an estimated $13.7M.

  • 75 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2017, up from 69 in Q2 2017.
  • Funds reported $585M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2017, up 74% quarter-over-quarter.
  • 19 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2017 and 13 closed out, a net change of +6 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2017 was Vivo Capital, an estimated $60M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2017 was RA Capital Management, an estimated $13.7M sold.

Based on aggregated 13F filings for Q3 2017.